Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

• ClinicalTrials.gov Identifier: NCT00956813
• Recruitment Status: Completed
• First Posted: August 11, 2009
• Results First Posted: April 4, 2017
• Last Update Posted: April 4, 2017
• Sponsor: Alliance for Clinical Trials in Oncology
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology

Tracking Information

• First Submitted Date: August 8, 2009
• First Posted Date: August 11, 2009
• Results First Submitted Date: November 29, 2016
• Results First Posted Date: April 4, 2017
• Last Update Posted Date: April 4, 2017
• Study Start Date: October 2009
• Actual Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 16, 2017)

To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary. [ Time Frame: Baseline and 7 weeks ]

The intra-patient difference in hot flash activity between baseline (study week 1) and treatment termination (study week 7) is the primary endpoint. The hot flash activity will be measured by the weekly average hot flash score which is a composite entity of both frequency and severity of hot flashes. The hot flash severities are graded from 1 to 4, ranging from mild, to moderate, to severe to very severe. The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The average daily hot flash score during the baseline week was compared to the average daily value during week 7. The primary method of analysis will be the independent sample t-test to examine the change of weekly average hot flash score from baseline to treatment termination between flaxseed and placebo arms.

• Original Primary Outcome Measures (submitted: August 8, 2009): Hot flash score at week 7

Current Secondary Outcome Measures (submitted: February 16, 2017)

• Toxicity as Measured by CTCAE v3.0 [ Time Frame: Up to 7 weeks ]
  Frequency and severity of adverse events were reported by patients weekly evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report.
• Change of Mood as Measured by the Profile of Mood States (POMS) [ Time Frame: Baseline and up to 7 weeks ]
  Profile of Mood States (POMS) was used to look at total mood disturbance as well as the subscales of tension-anxiety, fatigue-inertia, and vigor-activity. The POMS is a well known, well validated, reliable measure of psychological distress which includes 6 subscales of fatigue-inertia, vigor-activity, tension-anxiety, depression-dejection, anger-hostility, and confusion-bewilderment. The entire scale can be scored to provide a measure of total mood disturbance. The measure contains adjectives related to mood which are scored from 0 (not at all) to 4 (extremely). Individual scores were converted to a 0-100 scale where 100 is best quality of life. The change of mood as measured by the POMS from baseline to treatment termination between flaxseed versus placebo arms was compared using Kruskal-Wallis test. The mean change in total score for each arm is reported.
• Change of Menopause Specific Quality of Life as Measured by the Menopause Specific Quality of Life (MENQOL) [ Time Frame: Baseline and up to 7 weeks ]
  The change in quality of life as measured by the MENQOL from baseline to treatment termination between flaxseed versus placebo arms was evaluated. On a 0-6 scale, patients were asked to answer questions in in each of 4 domain scores (Vasomotor, Psychosocial, Physical, Sexual) Scores were converted to a 0-100 scale where 100 is best QOL. The change in score from baseline to end of treatment were analyzed separately for each domain. Here we report the mean change in score for each category.
• Change of Daily Interference as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS) [ Time Frame: Baseline and up to 7 weeks ]
  The change of daily interference as measured by the HFRDIS from baseline to treatment termination between flaxseed versus placebo arms was evaluated with an independent t-test for continuous data. On a 0-10 scale, patients were asked to describe how hot flashes interfered with 10 different aspects of their life (work, social activities, leisure activities, sleep, mood, concentration, relationships with others, sexuality, enjoyment of life and overall quality of life). Scores were converted to a 0-100 scale where 100 is best QOL.The HFRDIS total score was the average of the 10 individual questions. The change in total score from baseline to end of treatment was analyzed between the groups using a Kruskal-Wallace test.

Original Secondary Outcome Measures (submitted: August 8, 2009)

• Toxicity as measured by CTCAE v3.0
• Mood
• General menopausal symptoms
• Hot flash-related daily interference on activities

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
• Official Title: Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes

Brief Summary

RATIONALE: Estrogen can relieve the symptoms of menopause, but can also cause the growth of breast cancer cells. Flaxseed may reduce the number of hot flashes and improve mood and quality of life in postmenopausal women not receiving estrogen therapy.

PURPOSE: This randomized phase III trial is studying flaxseed to see how well it works in treating postmenopausal women with hot flashes who have a history of breast cancer or other cancer or who do not wish to take estrogen therapy.

Detailed Description

OBJECTIVES:

• To evaluate the efficacy of flaxseed on hot flash scores in women with a history of breast cancer or other cancer or in women who do not wish to take estrogen therapy for fear of increased risk of breast cancer as measured by a daily prospective hot flash diary.
• To evaluate the side effect profile of flaxseed in this population.
• To evaluate the effects of flaxseed on mood (per the Profile of Mood States) and broader menopausal symptoms (per the MENQOL), daily interference from hot flashes (per the HFRDIS), and perception of benefit (per Global Impression of Change).

OUTLINE: Patients are stratified according to age (18-49 years vs ≥ 50 years); treatment with tamoxifen citrate, selective estrogen receptor modulators, or aromatase inhibitors (yes vs no); duration of hot flashes (≤ 9 months vs > 9 months); and daily frequency of hot flashes (4-9 vs ≥ 10). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
• Arm II: Patients receive oral placebo bar once daily. In both arms, treatment continues for 6-12 weeks. Patients in arm II may crossover to receive treatment as in arm I after 6 weeks.

Patients complete questionnaires (Hot Flash Diary, Side Effect Experience Questionnaire, Profile of Mood States, Hot Flash Related Daily Interference Scale, and Menopause Specific Quality of Life) at baseline and periodically during treatment. Patients are contacted by telephone at the end of weeks 2, 4, 5, and 7 to assess product tolerability, document compliance, encourage completion of questionnaires, and address problems.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Supportive Care

Condition

• Breast Cancer
• Hot Flashes
• Menopausal Symptoms
• Unspecified Adult Solid Tumor, Protocol Specific

Intervention

• Dietary Supplement: flaxseed
  Given orally
• Other: placebo
  Given orally

Study Arms

• Experimental: Arm I
  Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
  Intervention: Dietary Supplement: flaxseed
• Placebo Comparator: Arm II
  Patients receive oral placebo bar once daily.
  Intervention: Other: placebo

Publications *

• Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 2012 Jan;19(1):48-53. doi: 10.1097/gme.0b013e318223b021.
• Pruthi S, Qin R, Terstriep SA, et al.: The evaluation of flaxseed for hot flashes: results of a randomized, controlled trial, NCCTG study N08C7. [Abstract] J Clin Oncol 29 (Suppl 15): A-CRA9015, 2011.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: September 16, 2009): 210
• Original Estimated Enrollment (submitted: August 8, 2009): 219
• Actual Study Completion Date: May 2013
• Actual Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)

Eligibility Criteria

• Bothersome hot flashes, defined by their occurrence ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention

  • Presence of hot flashes for ≥ 1 month

• Meets 1 of the following criteria:

  • History of breast cancer or other cancer (currently without malignant disease)
  • No history of breast cancer and wishes to avoid estrogen due to a perceived increased risk of breast cancer
• Hormone receptor status not specified
• Postmenopausal as defined by 1 of the following*:

NOTE: *Women with ≥ 1 ovary but without a uterus should be deemed postmenopausal by either age > 55 OR a combination of estrogen within a postmenopausal range (per local lab) and follicle-stimulating hormone > 40 mIU/mL

• Absence of a period in the past 12 months

• Bilateral oophorectomy

  • ECOG performance status 0-1
  • Life expectancy ≥ 6 months
  • Able to complete questionnaire(s) alone or with assistance
  • No diabetes requiring oral or injectable antihyperglycemics
  • No hypotension
  • No history of allergic or other adverse reaction to flaxseed
  • No irritable bowel syndrome, colitis, Crohn disease, or any gastrointestinal condition where the patient should not consume and/or has an intolerance/allergies to seeds or nuts
  • At least 4 weeks since prior and no concurrent or planned androgens, estrogens, or progestational agents

• Tamoxifen, raloxifene, or aromatase inhibitors are allowed provided the patient has been on a constant dose for ≥ 4 weeks and is not expected to stop the medication during study treatment

  • At least 4 weeks since prior and no concurrent anti-cancer therapies of any kind

• Trastuzumab allowed

  • No concurrent treatment with other anti-cancer therapies of any kind except for trastuzumab or endocrine therapies
  • No concurrent (≤ 7 days prior to registration) or planned use of other agents for treating hot flashes (i.e., gabapentin, clonidine, antidepressants, estrogen treatment, megestrol acetate, or Bellergal)
• Stable dose of vitamin E (as a general vitamin supplement) allowed provided it is ≤ 800 IU/day, it was started > 30 days before study initiation, and is to be continued through study period

• Patients who have been using antidepressants for mood and have been on a stable dose for over a month and meet the eligibility criteria for hot flash frequency and duration are eligible

  • No concurrent anticoagulants or anti-platelets (1 mg of Coumadin for central line patency allowed)

• Aspirin allowed (≤ 81 mg)

  • No concurrent anti-hypertensives
  • No other concurrent herbal supplements for any reason, including soy and soy supplements (i.e., powders, pills, or milk)

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00956813
• Other Study ID Numbers: N08C7; NCCTG-N08C7; CDR0000644811 ( Registry Identifier: PDQ (Physician Data Query) ); NCI-2011-01928 ( Registry Identifier: CTRP (Clinical Trials Reporting System) )
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Alliance for Clinical Trials in Oncology
• Original Responsible Party: Jan C. Buckner, North Central Cancer Treatment Group
• Current Study Sponsor: Alliance for Clinical Trials in Oncology
• Original Study Sponsor: North Central Cancer Treatment Group
• Collaborators: National Cancer Institute (NCI)

Investigators

• Study Chair: Debra Barton, RN, PhD, AOCN, FAAN; Mayo Clinic

• PRS Account: Alliance for Clinical Trials in Oncology
• Verification Date: February 2017